Publikasi Scopus 2024 per tanggal 30 Juni 2024 (499 artikel)

Aggarwal B.; Al-Moamary M.; Allehebi R.; Alzaabi A.; Al-Ahmad M.; Amin M.; Damayanti T.; Van Tho N.; Quyen P.T.L.; Sriprasart T.; Poachanukoon O.; Yu-Lin A.B.; Ismail A.I.; Limpin M.E.B.; Koenig S.; Levy G.; Phansalkar A.; Rafih F.; Silvey M.; Miriams L.; Milligan G.
Aggarwal, Bhumika (23007797900); Al-Moamary, Mohamed (6603571313); Allehebi, Riyad (57259477200); Alzaabi, Ashraf (6507944563); Al-Ahmad, Mona (8927100400); Amin, Muhammad (57204760796); Damayanti, Triya (36058523500); Van Tho, Nguyen (35504306500); Quyen, Pham Thi Le (59172036400); Sriprasart, Thitiwat (55710988900); Poachanukoon, Orapan (13408603400); Yu-Lin, Andrea Ban (57218947426); Ismail, Ahmad Izuanuddin (57191495343); Limpin, Maria Encarnita B. (58159922900); Koenig, Steven (59171795000)
23007797900; 6603571313; 57259477200; 6507944563; 8927100400; 57204760796; 36058523500; 35504306500; 59172036400; 55710988900; 13408603400; 57218947426; 57191495343; 58159922900; 59171795000; 7402345745; 55948998300; 59172036500; 57985632800; 59172036600; 21734993200
APPaRENT 3: Asthma Patients’ and Physicians' Perspectives on the Burden and Management of Asthma in Seven Countries
2024
Advances in Therapy
0
General Medicines, GSK, 23 Rochester Park, #06-01, GSK Asia House, Singapore, 139234, Singapore; Department of Medicine, College of Medicine, King Saudi Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia; Department of Pulmonology, King Fahad Medical City, Riyadh, Saudi Arabia; College of Medicine, Alfaisal University, Riyadh, Saudi Arabia; Internal Medicine Department, College of Medicine and Health Sciences, UAE University, Abu Dhabi, United Arab Emirates; Respirology Division, Zayed Military Hospital, Abu Dhabi, United Arab Emirates; Microbiology Department, College of Medicine, Kuwait University, Kuwait City, Kuwait; Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Airlangga Hospital, Surabaya, Indonesia; Department of Pulmonology and Respiratory Medicine, Faculty of Medicine Universitas Indonesia, Persahabatan Hospital National Respiratory Center, Jakarta, Indonesia; Department of Tuberculosis and Lung Diseases, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Viet Nam; Respiratory Center, Bach Mai Hospital, Hanoi, Viet Nam; Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand; Center of Excellence for Allergy, Asthma and Pulmonary Diseases and Department of Pediatrics, Thammasat University, Pathum Thani, Thailand; Respiratory Unit, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia; Faculty of Medicine, Universiti Teknologi MARA, Sungai Buloh Campus, Selangor, Malaysia; Pulmonary and Critical Care Medicine Division, Philippine Heart Center, Quezon City, Philippines; St. Claire HealthCare, Morehead, KY, United States; GSK, Panama City, Panama; GSK, Mumbai, India; GSK, Dubai, United Arab Emirates; Adelphi Real World, Bollington, United Kingdom
Aggarwal B., General Medicines, GSK, 23 Rochester Park, #06-01, GSK Asia House, Singapore, 139234, Singapore; Al-Moamary M., Department of Medicine, College of Medicine, King Saudi Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia; Allehebi R., Department of Pulmonology, King Fahad Medical City, Riyadh, Saudi Arabia, College of Medicine, Alfaisal University, Riyadh, Saudi Arabia; Alzaabi A., Internal Medicine Department, College of Medicine and Health Sciences, UAE University, Abu Dhabi, United Arab Emirates, Respirology Division, Zayed Military Hospital, Abu Dhabi, United Arab Emirates; Al-Ahmad M., Microbiology Department, College of Medicine, Kuwait University, Kuwait City, Kuwait; Amin M., Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Airlangga Hospital, Surabaya, Indonesia; Damayanti T., Department of Pulmonology and Respiratory Medicine, Faculty of Medicine Universitas Indonesia, Persahabatan Hospital National Respiratory Center, Jakarta, Indonesia; Van Tho N., Department of Tuberculosis and Lung Diseases, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Viet Nam; Quyen P.T.L., Respiratory Center, Bach Mai Hospital, Hanoi, Viet Nam; Sriprasart T., Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand; Poachanukoon O., Center of Excellence for Allergy, Asthma and Pulmonary Diseases and Department of Pediatrics, Thammasat University, Pathum Thani, Thailand; Yu-Lin A.B., Respiratory Unit, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia; Ismail A.I., Faculty of Medicine, Universiti Teknologi MARA, Sungai Buloh Campus, Selangor, Malaysia; Limpin M.E.B., Pulmonary and Critical Care Medicine Division, Philippine Heart Center, Quezon City, Philippines; Koenig S., St. Claire HealthCare, Morehead, KY, United States; Levy G., GSK, Panama City, Panama; Phansalkar A., GSK, Mumbai, India; Rafih F., GSK, Dubai, United Arab Emirates; Silvey M., Adelphi Real World, Bollington, United Kingdom; Miriams L., Adelphi Real World, Bollington, United Kingdom; Milligan G., Adelphi Real World, Bollington, United Kingdom
Introduction: Asthma management is strongly dependent on physician and patient beliefs and perceptions about the disease and its long-term treatment. The APPaRENT 3 study was conducted to explore factors influencing treatment choice and to understand patients’ and physicians’ attitudes and perspectives on the use of controller inhalers in regular versus flexible dosing for asthma management. Methods: This cross-sectional survey of patients with asthma and treating physicians was conducted in seven countries: Indonesia, Malaysia, Philippines, Thailand, Vietnam (patient survey only), Saudi Arabia, and the United Arab Emirates. Assessment was carried out through an online/face-to-face questionnaire, where patients’ viewpoints were focused on their attitudes and beliefs about asthma and treatment adherence, whereas physicians’ viewpoints were gathered on their attitudes and beliefs about asthma management, knowledge of and adherence to asthma treatment guidelines, and asthma treatment regimens. Results: Overall, 1400 patients (mean age, 34 years) and 599 physicians (mean age, 43 years) were included in the survey. Physicians similarly prioritised symptom control (39%) and exacerbation reduction (40%) in moderate asthma, whereas patients prioritised symptom control (41%) over exacerbation reduction (22%). Although both groups (physicians, 86%; patients, 84%) perceived asthma as well-controlled, poor management was evident based on Asthma Control Test (ACT) scores (mean, 15.7; standard deviation, 4.14; 82% had an ACT score < 20) and high symptom burden (39% reported nighttime awakenings or early mornings ≥ 2 nights/week). Most patients (76%) with moderate asthma were prescribed regular dosing, with the most common treatment being inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA) with as-needed inhaled short-acting β2-agonist (SABA; 20%). Among patients on maintenance and reliever therapy, 93% of patients received a separate inhaled reliever. Conclusions: Despite high symptom burden, patients overestimated their level of asthma control. Physicians prioritised controlling symptoms and reducing exacerbations as treatment goals for moderate asthma, often prescribing regular dosing with ICS/LABA with as-needed inhaled SABA. © The Author(s) 2024.
Asthma; Asthma control; Asthma exacerbation; Asthma regimen; Guideline adherence; Patient viewpoints; Physician perspectives
GlaxoSmithKline, GSK
Adelphi Real World was responsible for data collection and analysis, which was funded by GSK. Ebru Yildiz, an employee of GSK, was involved in study planning and set-up activities. Mohamed Hamouda and Amal Kumaran, employees of GSK, provided critical inputs during manuscript review. The study planning and set-up were supported by GSK employees in seven countries: Indonesia (Cindy Patricia), Malays
Adis
0741238X
Article
Q1
1076
3722